Medicare drug negotiation delayed for new peptide class—four extra years of high prices

What it does

This bill amends the Medicare drug price negotiation program to give engineered cyclic peptides (a specific class of synthetic drugs made from amino acids) an 11-year exclusion period before they can be subject to price negotiation, instead of the standard 7-year period. The effect is to delay Medicare's ability to negotiate prices on these drugs for four additional years, protecting manufacturers' pricing power during that window.

Why we flagged it

The bill's operative mechanism is a targeted extension of pricing exclusivity for a narrowly defined drug class. While framed as a technical amendment, it functions as a direct subsidy to manufacturers of engineered cyclic peptides by delaying Medicare's negotiating power.

What the text implies

• The 11-year exclusion applies only to engineered cyclic peptides meeting all six criteria (amino acid polymer, cyclic structure, ≤40 amino acids, genetically encoded library screening, non-natural, self-administered). This narrow definition may have been reverse-engineered to match specific drugs in development or recently approved, creating a de facto single-company or single-drug carve-out witho
• The effective date applies to 'lists published on or after' enactment, meaning drugs already on negotiation lists are unaffected—the benefit flows only to future drugs meeting the definition, suggesting this targets a pipeline of anticipated products.
• Extending exclusivity by 4 years (57% longer than the baseline) for a specific molecular class while leaving other biologics at 7 years creates a precedent for class-specific carve-outs, potentially inviting similar amendments for other drug categories.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries and the federal government will pay higher prices for engineered cyclic peptides for an additional four years before price negotiation becomes available. The extension directly delays cost containment and shifts financial burden to seniors and taxpayers.

Who stands to gain

• Manufacturers of engineered cyclic peptides
• Pharmaceutical companies with pipeline drugs in this class

Named in the bill

Social Security Act, Medicare, Drug Price Negotiation Program, Section 1192(e), engineered cyclic peptides

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• May 15, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 15, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $50,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Joseph Morelle, the sponsor, reported $934,875 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• Merck & Co., Inc — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.